SG11201901063SA - Therapeutic agents for neurodegenerative diseases - Google Patents
Therapeutic agents for neurodegenerative diseasesInfo
- Publication number
- SG11201901063SA SG11201901063SA SG11201901063SA SG11201901063SA SG11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA SG 11201901063S A SG11201901063S A SG 11201901063SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- begbroke
- pct
- neurodegenerative diseases
- english
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 208000012639 Balance disease Diseases 0.000 abstract 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 February 2018 (15.02.2018) WIPO I PCT Iiiimmoilloiollmonoloomolomioluilioluovom (10) International Publication Number WO 2018/029658 Al (51) International Patent Classification: A61K 31/13 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/IB2017/054929 (22) International Filing Date: 11 August 2017 (11.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1613829.9 11 August 2016 (11.08.2016) GB 1702551.1 16 February 2017 (16.02.2017) GB 1705766.2 10 April 2017 (10.04.2017) GB 1706867.7 28 April 2017 (28.04.2017) GB (71) Applicant: INTRABIO LIMITED [GB/GB]; Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke Oxfordshire 0Y5 1PF (GB). (72) Inventor: STRUPP, Michael; c/o The Department of Neu- rology and German Center for Vertigo and Balance Dis- orders, Ludwig-Maximilians-University Hospital Munich, Campus Grosshadern, Marchioninistr. 15, 81377 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) (54) Title: THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES TOTAL CSS -ALL 4 5 -o-6 7 -tt- 8 -V-9 -o-10 100 200 300 400 500 600 700 TREATMENT (DAYS) FIG. 10A 1-1 (57) : The present disclosure provides for treating neurodegenerative diseases comprising administering acetyl-leucine or a o pharmaceutically acceptable salt thereof. [Continued on next page] WO 2018/029658 Al MIDEDIM111101111111111111111111111111111111111111101111111110111111111111111111 Published: — with international search report (Art. 21(3))
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613829.9A GB201613829D0 (en) | 2016-08-11 | 2016-08-11 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1702551.1A GB201702551D0 (en) | 2017-02-16 | 2017-02-16 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1705766.2A GB201705766D0 (en) | 2017-04-10 | 2017-04-10 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| GBGB1706867.7A GB201706867D0 (en) | 2017-04-28 | 2017-04-28 | Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage |
| PCT/IB2017/054929 WO2018029658A1 (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901063SA true SG11201901063SA (en) | 2019-03-28 |
Family
ID=59859424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901063SA SG11201901063SA (en) | 2016-08-11 | 2017-08-11 | Therapeutic agents for neurodegenerative diseases |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20200179320A1 (en) |
| EP (2) | EP3416631B1 (en) |
| JP (3) | JP6957602B2 (en) |
| KR (2) | KR20220093385A (en) |
| CN (3) | CN109789114A (en) |
| AU (2) | AU2017308865B2 (en) |
| BR (1) | BR112019002730A2 (en) |
| CA (1) | CA3033564A1 (en) |
| CY (1) | CY1121930T1 (en) |
| DK (1) | DK3416631T3 (en) |
| ES (1) | ES2733677T3 (en) |
| HR (1) | HRP20191055T1 (en) |
| HU (1) | HUE045043T2 (en) |
| IL (3) | IL310799A (en) |
| LT (1) | LT3416631T (en) |
| MA (2) | MA43828B1 (en) |
| MD (1) | MD3416631T2 (en) |
| ME (1) | ME03454B (en) |
| MX (2) | MX2019001575A (en) |
| PL (1) | PL3416631T3 (en) |
| PT (1) | PT3416631T (en) |
| RS (1) | RS59048B1 (en) |
| RU (2) | RU2756519C2 (en) |
| SG (1) | SG11201901063SA (en) |
| SI (1) | SI3416631T1 (en) |
| TN (1) | TN2019000033A1 (en) |
| WO (1) | WO2018029658A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| KR102549684B1 (en) * | 2017-10-18 | 2023-06-29 | 인트라바이오 리미티드 | Treatments for neurodegenerative diseases |
| WO2019159110A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| CN113348018A (en) * | 2018-12-06 | 2021-09-03 | 内在生物技术有限公司 | Deuterated analogs of acetyl-leucine |
| EP3934637A1 (en) | 2019-03-02 | 2022-01-12 | IntraBio Ltd | Leucine, acetyl leucine, and related analogs for treating disease |
| WO2021055443A1 (en) * | 2019-09-17 | 2021-03-25 | Hoffmann-La Roche Inc. | Improvements in personalized healthcare for patients with movement disorders |
| CA3164545A1 (en) * | 2020-01-13 | 2021-07-22 | Michael Strupp | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (en) * | 2006-09-13 | 2010-01-15 | Pf Medicament | TREATMENT OF VERTIGS BY ACETYL-L-LEUCINE. |
| TN2010000251A1 (en) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
-
2017
- 2017-08-11 CN CN201780059708.6A patent/CN109789114A/en active Pending
- 2017-08-11 PL PL17767934T patent/PL3416631T3/en unknown
- 2017-08-11 MX MX2019001575A patent/MX2019001575A/en unknown
- 2017-08-11 IL IL310799A patent/IL310799A/en unknown
- 2017-08-11 HU HUE17767934A patent/HUE045043T2/en unknown
- 2017-08-11 RU RU2019106506A patent/RU2756519C2/en active
- 2017-08-11 SG SG11201901063SA patent/SG11201901063SA/en unknown
- 2017-08-11 LT LTEP17767934.7T patent/LT3416631T/en unknown
- 2017-08-11 IL IL310801A patent/IL310801A/en unknown
- 2017-08-11 PT PT17767934T patent/PT3416631T/en unknown
- 2017-08-11 ES ES17767934T patent/ES2733677T3/en active Active
- 2017-08-11 SI SI201730071T patent/SI3416631T1/en unknown
- 2017-08-11 TN TNP/2019/000033A patent/TN2019000033A1/en unknown
- 2017-08-11 KR KR1020227021012A patent/KR20220093385A/en not_active IP Right Cessation
- 2017-08-11 AU AU2017308865A patent/AU2017308865B2/en active Active
- 2017-08-11 BR BR112019002730-0A patent/BR112019002730A2/en active Search and Examination
- 2017-08-11 RU RU2021128045A patent/RU2021128045A/en unknown
- 2017-08-11 CN CN202310627214.0A patent/CN116459244A/en active Pending
- 2017-08-11 CA CA3033564A patent/CA3033564A1/en active Pending
- 2017-08-11 EP EP17767934.7A patent/EP3416631B1/en active Active
- 2017-08-11 DK DK17767934.7T patent/DK3416631T3/en active
- 2017-08-11 MA MA43828A patent/MA43828B1/en unknown
- 2017-08-11 ME MEP-2019-169A patent/ME03454B/en unknown
- 2017-08-11 WO PCT/IB2017/054929 patent/WO2018029658A1/en active Application Filing
- 2017-08-11 MA MA047521A patent/MA47521A/en unknown
- 2017-08-11 JP JP2019507819A patent/JP6957602B2/en active Active
- 2017-08-11 MD MDE20190027T patent/MD3416631T2/en unknown
- 2017-08-11 RS RS20190801A patent/RS59048B1/en unknown
- 2017-08-11 KR KR1020197007032A patent/KR102413756B1/en active IP Right Grant
- 2017-08-11 EP EP19174007.5A patent/EP3583940A1/en active Pending
- 2017-08-11 IL IL264641A patent/IL264641B1/en unknown
- 2017-08-11 US US16/324,353 patent/US20200179320A1/en active Pending
- 2017-08-11 CN CN202310629563.6A patent/CN116492328A/en active Pending
-
2019
- 2019-02-07 MX MX2021006901A patent/MX2021006901A/en unknown
- 2019-06-12 HR HRP20191055TT patent/HRP20191055T1/en unknown
- 2019-07-16 CY CY20191100759T patent/CY1121930T1/en unknown
-
2021
- 2021-10-06 JP JP2021164793A patent/JP2022003085A/en active Pending
-
2023
- 2023-03-15 US US18/183,972 patent/US20230210799A1/en active Pending
- 2023-04-05 AU AU2023202121A patent/AU2023202121A1/en active Pending
- 2023-09-08 JP JP2023146465A patent/JP2023175762A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901925RA (en) | Methods of treating acute kidney injury |